Research programme: metabolic disorders therapy - DeveloGen

Drug Profile

Research programme: metabolic disorders therapy - DeveloGen

Alternative Names: DG 70 inhibitors; DG070 inhibitors

Latest Information Update: 06 Sep 2010

Price : $50

At a glance

  • Originator DeveloGen
  • Developer DeveloGen; Evotec AG
  • Class Small molecules
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Metabolic syndrome; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 02 Sep 2010 DeveloGen has been acquired by Evotec AG
  • 29 Apr 2008 Lead optimisation stage development of DG070 inhibitors is ongoing
  • 12 Sep 2003 Preclinical trials in Metabolic syndrome in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top